Alzheimer's disease (AD) is one of the
neurodegenerative diseases characterized by the deposition of
amyloid-β-
protein (Aβ) as
senile plaques in the brain parenchyma and phosphorylated-tau accumulation as neurofibrillary tangles in the neurons. Although details of the disease pathomechanisms remain unclear, Aβ likely acts as a key
protein for AD initiation and progression, followed by abnormal tau phosphorylation and neuronal death (
amyloid-cascade hypothesis). According to this hypothesis, Aβ immunization
therapies are created to eliminate Aβ from the brain, and to prevent the neurons from damage by these pathogenic
proteins. There are two methods for Aβ immunotherapies: active and passive immunization. Previous studies have shown Aβ removal and improved cognitive function in animal models of AD. Clinical trials on various drugs, including
AN1792,
bapineuzumab, and
solanezumab, have been carried out; however, all trials have failed to demonstrate apparent clinical benefits. On the contrary, side effects emerged, such as
meningoencephalitis, vasogenic
edema, which are currently called
amyloid related imaging abnormalities (ARIA)-E and microhemorrhage (ARIA-H). In neuropathological studies of immunized cases, Aβ was removed from the brain parenchyma and phosphorylated-tau was reduced in the neuronal processes. Moreover, deterioration of the
cerebral amyloid angiopathy (CAA) and an increase of microhemorrhages and microinfarcts were described. Aβ is cleared from the brain mainly via the lymphatic drainage pathway. ARIA could stem from severe CAA due to dysfunction of the drainage pathway after
immunotherapy. Aβ immunization has a potential of cure for AD patients, although the above-described problems must be overcome before applying this
therapy in clinical treatment.